Status: Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Xiamen UniversityUpdated: Feb 19, 2025Locations: 1
Eligibility criteria
Peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma confirmed by histopathol... [+6]
Patients with central nervous system (CNS) or meningeal invasion [+19]